Peter Max
- CEO Partner
Transaction Description
Gemstone Capital acted as financial advisor in Brain+’s IPO (Initial Public offering). The IPO was concluded with a total subscription percentage of 169%. Therefore, Brain+ received gross proceeds of DKK 15 million and converted all debt from the pre-IPO funding as described in the Company Description. Of the maximum IPO amount, 50.1% or DKK 7.5 million was pre-subscribed. This means that a total of DKK 7.5 million was offered for open public subscription.
Contact Person
Company Description
Brain+ is a pioneer in developing medical software to treat the cognitive symptoms of dementia, and the most common cause of dementia, namely Alzheimer’s disease. Together with world-leading experts and institutions, the Company digitize the best-in-class, non-drug dementia therapies, and make them broadly available on standard digital devices – for use both in people’s homes and at healthcare clinics. This approach is referred to as Digital Therapeutics or Digital Medicine.